News of Note - March 2, 2023

BULL BEAR BRES|NAHAN

Thursday, March 2, 2023

As of -> 09:30 EET

Tough sledding in healthcare of late, admittedly with glimmers of hope, though one of the great aspects of the space is that with time come readouts - oh and massive cash generation..

While the sector takes up a lot of my active thinking time, stepping back there are other big things going on - foremost what comes to mind is 're-shoring'.. That is a massive trend to ponder and is highly inflationary; which, I think, is why we're seeing this 'other-shoring'..

A recasting of globalization, Asia exChina and Mexico are screaming opportunities for companies.. What then of Central and South America, Africa, etc??

Perhaps we finally get beyond mere commodities and local economies?

In the interim, with the FX volatility we've had, it is tough to get *too* excited about EM - though I find myself reading more on varying stories I've not looked at in some time..

😊

Br. -john

*PRESS RELEASES*

ABI BB | BUD

Anheuser Busch Inbev

Release

https://www.ab-inbev.com/assets/pressreleases/2023/FY22_AB%20InBev_Press%20Release_FINAL_EN.pdf

Report

https://www.ab-inbev.com/assets/pressreleases/2023/AB%20InBev_2022%20Annual%20Report_FINAL.pdf

Financials

https://www.ab-inbev.com/assets/pressreleases/2023/FY%20Financial%20Report%202022.pdf

Hub

https://www.ab-inbev.com/investors/results-center/

Webcast

https://event.webcasts.com/starthere.jsp?ei=1582179&tp_key=09703ba2dc

STLAP FP | STLAM IM | STLA & ACA FP

Stellantis & Crédit Agricole

Leasys and Free2move Lease Consolidation: New Top Leadership Announced

Philippe de Rovira, Stellantis Chief Affiliates Officer, and Stéphane Priami, Crédit Agricole S.A Deputy General Manager in charge of Specialised Financial Services and CEO of Crédit Agricole Consumer Finance, have announced the Top Leadership for the NewCo to be created by the upcoming consolidation of the two leasing companies’ business
Richard Bouligny, Group Deputy CEO – Automotive and Mobility of Crédit Agricole Consumer Finance, will be the Chairman, and Rolando D’Arco currently Leasys CEO, will be appointed as CEO of the new European player
Stellantis and Crédit Agricole Consumer Finance will each have 50% shareholding rights

NOVOB DC | NVO

Novo Nordisk

To expand R&D presence in greater Boston area

SOBI SS & SAN FP | SNY

Sobi Sanofi

Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A - SOBI

Primary endpoint was met with no factor VIII inhibitors detected, confirming the safety profile of efanesoctocog alfa in previously treated patients under 12 years of age
The completion of XTEND-Kids represents the final milestone needed for regulatory submission in the EU

Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO™ to redefine expectations for treatment of children <12 years of age with hemophilia A - SANOFI

GSK LN | GSK

GSK

GSK and Pfizer are leading the RSV race and my hunch is they split the market in older adults, efficacy is likely similar and on the AE/safety side you'd expect things to be similar though GSK's shot is adjuvanted and might be more off putting for patients - the GBS issue will be monitored and if anything I suspect it's an issue for both.. On the maternal/ infant side it is hard to imagine Sanofi and Sobi taking huge share purely from the cost standpoint of a mAb vs vaccine.. At any rate, these three (Sanofi, GSK, Pfizer) have great sales teams and other products to offer along side these - hard to imagine others really breaking in..

FDA Ad Com votes to support GSK RSV OA vaccine

Committee votes unanimously that the data support the effectiveness of the vaccine, and 10-2 that the data support the safety of the vaccine
FDA decision on US approval expected by 3 May 2023, with the potential for the vaccine to be the first approved for older adults
Evidence reviewed by the Committee was supported by pivotal data recently published in the New England Journal of Medicine

FORTUM FH

Fortum

Updates business and reporting structure, and appoints new members to the Leadership Team

Renews strategy to drive clean transition; new financial targets and dividend policy and more ambitious environmental targets

Release/ Report

https://mb.cision.com/Public/15253/3726294/ba273ea35d7f47df.pdf

Presentation

https://www.fortum.com/files/fortum-financial-statements-bulletin-2022-presentation/download?attachment

Webcast

https://fortum.videosync.fi/2022-q4-results

ARGX BB | ARGX

argenx [bio]

Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

Announces Planned Transition of Chief Operating Officer

MRK GY

Merck KGaA

Release

https://www.merckgroup.com/en/news/q4-2022-02-03-2023.html

Report

https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2022-q4/en/2022-Q4-Report-EN.pdf

Presentation

https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2022-q4/en/2022-Q4-Media-Presentation-EN.pdf

Webcast

https://edge.media-server.com/mmc/p/wa4o8q5i

GURN SW

Gurit

Release/ Report

https://www.gurit.com/-/media/gurit/attachments/reports/2023/gurit-annualreport-2022-sp.pdf?la=en&hash=8EBF9E1AC68F24F3D7AF87F1B28ECBFCBEF89552

Presentation

https://www.gurit.com/-/media/gurit/attachments/reports/2023/2023_03_02_fy2022_presentation-gurit-holding-ag.pdf?la=en&hash=5CA2C42CEC4B0FAC183A0B870AFCB44882D9E656

Webcast

https://media.choruscall.eu/mediaframe/webcast.html?webcastid=u7LmbtFN

DICE

DICE Therapeutics [bio]

Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

Title: DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis

CYTK

Cytokinetics [bio]

Reports Fourth Quarter 2022 Financial Results

PFE & BNTX

Pfizer & BioNTech

Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years

STLAP FP | STLAM IM | STLA & KCHOL TI & TOASO TI

Stellantis & Koç Holding & Tofas

Strengthen Tofaş and Enhance Partnership in Türkiye

Commercial activities for all Stellantis brands in Türkiye will be consolidated under Tofaş, enabling increased business synergies and value creation for all Stellantis brands and segments along with Tofaş
Stellantis will allocate a new production of the “K0” to Tofaş, in both mid-size light commercial vehicle and passenger car versions, planned for five brands, with target production launch from beginning of 2025
Current Doblo production is planned to continue until the start of work on the production lines of the “K0” model in July 2023
Current Fiat Egea/Tipo project will be extended until end of 2025
Strategic collaboration will more efficiently bring customer-centric and industry-leading products to the customers

AMGN

Amgen

To Present New Repatha (evolocumab) and Olpasiran Data at ACC

PEG

Public Service Enterprise Group

Proposes Third Phase of Gas System Modernization Program that Strengthens the State's Infrastructure and Sustains Thousands of Jobs

ALLO

Allogene Therapeutics [bio]

Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy

LLY

Eli Lilly

Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month

BNTX

BioNTech [bio]

Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

STWD

Starwood Property Trust

Release

https://ir.starwoodpropertytrust.com/news/press-release-details/2023/Starwood-Property-Trust-Reports-Results-for-the-Quarter-and-Year-Ended-December-31-2022/default.aspx

Presentation

https://s22.q4cdn.com/794586023/files/doc_financials/2022/q4/STWD-Earnings-Deck-YE-2022-FINAL.pdf

Webcast

https://viavid.webcasts.com/starthere.jsp?ei=1590342&tp_key=22843928ad

ZNTL

Zentalis Pharmaceuticals [bio]

Reports Full Year 2022 Financial Results and Operational Updates

CDTX

Cidara [bio]

Announces Promising Interim Phase 2a Data Assessing the Safety and Efficacy of a Single Dose of CD388 in an Influenza Challenge Model

MRK Merck

Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer

In pivotal study, KEYTRUDA® (pembrolizumab) in combination with chemotherapy before surgery and continuing as a single agent after surgery showed a statistically significant improvement in EFS versus pre-operative chemotherapy
KEYTRUDA-based regimen also showed statistically significant improvements in key secondary endpoints of pathological complete response and major pathological response
FDA accepted application based on these data and set PDUFA date of October 16, 2023

ORNBV FH & BAYN GY

Orion & Bayer

Darolutamide receives EU approval for additional indication in prostate cancer

European Commission granted approval of darolutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Approval is based on Phase III ARASENS trial data

PHIA NA | PHG

Koninklijke (Royal) Philips

Highlights AI-powered integrated diagnostic approach at ECR 2023

*ARTICLES, ETC.*

Nature

How did life begin? One key ingredient is coming into view

A Nobel-prizewinning scientist’s team has taken a big step forward in its quest to reconstruct an early-Earth RNA capable of building proteins.

JAMA

Characterizing Epidemiology and Burden of Disease in Alopecia Areata—Making It Count

Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

Bloomberg

Bank CDs Are an Insult to America’s Savers

Big financial institutions don’t feel the need to offer competitive rates on certificates of deposit, which are universally below the world’s safest asset: Treasury bills.

The Satellite Hack Everyone Is Finally Talking About

Apple Suppliers Are Racing to Exit China, AirPods Maker Says